BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 20017885)

  • 1. PARP inhibitors and the treatment of breast cancer: beyond BRCA1/2?
    Frizzell KM; Kraus WL
    Breast Cancer Res; 2009; 11(6):111. PubMed ID: 20017885
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A selective eradication of human nonhereditary breast cancer cells by phenanthridine-derived polyADP-ribose polymerase inhibitors.
    Inbar-Rozensal D; Castiel A; Visochek L; Castel D; Dantzer F; Izraeli S; Cohen-Armon M
    Breast Cancer Res; 2009; 11(6):R78. PubMed ID: 19891779
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The inhibition and treatment of breast cancer with poly (ADP-ribose) polymerase (PARP-1) inhibitors.
    De Soto JA; Wang X; Tominaga Y; Wang RH; Cao L; Qiao W; Li C; Xu X; Skoumbourdis AP; Prindiville SA; Thomas CJ; Deng CX
    Int J Biol Sci; 2006; 2(4):179-85. PubMed ID: 16810332
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The clinical development of inhibitors of poly(ADP-ribose) polymerase.
    Calvert H; Azzariti A
    Ann Oncol; 2011 Jan; 22 Suppl 1():i53-9. PubMed ID: 21285153
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Poly(ADP-ribose) polymerase (PARP) inhibitors in BRCA1/2 cancer therapy].
    Kluzek K; Białkowska A; Koczorowska A; Zdzienicka MZ
    Postepy Hig Med Dosw (Online); 2012 Jun; 66():372-84. PubMed ID: 22706123
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [From poly(ADP-ribose) discovery to PARP inhibitors in cancer therapy].
    Schreiber V; Illuzzi G; Héberlé E; Dantzer F
    Bull Cancer; 2015 Oct; 102(10):863-73. PubMed ID: 26384693
    [TBL] [Abstract][Full Text] [Related]  

  • 7. BRCA2-deficient CAPAN-1 cells are extremely sensitive to the inhibition of Poly (ADP-Ribose) polymerase: an issue of potency.
    McCabe N; Lord CJ; Tutt AN; Martin NM; Smith GC; Ashworth A
    Cancer Biol Ther; 2005 Sep; 4(9):934-6. PubMed ID: 16251802
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PARP inhibitors in older patients with ovarian and breast cancer: Young International Society of Geriatric Oncology review paper.
    Liposits G; Loh KP; Soto-Perez-de-Celis E; Dumas L; Battisti NML; Kadambi S; Baldini C; Banerjee S; Lichtman SM
    J Geriatr Oncol; 2019 Mar; 10(2):337-345. PubMed ID: 30333088
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Poly(ADP-ribose) polymerase-1 inhibition: preclinical and clinical development of synthetic lethality.
    Leung M; Rosen D; Fields S; Cesano A; Budman DR
    Mol Med; 2011; 17(7-8):854-62. PubMed ID: 21424107
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Synthetic lethality and cancer therapy: lessons learned from the development of PARP inhibitors.
    Lord CJ; Tutt AN; Ashworth A
    Annu Rev Med; 2015; 66():455-70. PubMed ID: 25341009
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Poly(ADP-ribose)polymerase (PARP) inhibition and anticancer activity of simmiparib, a new inhibitor undergoing clinical trials.
    Yuan B; Ye N; Song SS; Wang YT; Song Z; Chen HD; Chen CH; Huan XJ; Wang YQ; Su Y; Shen YY; Sun YM; Yang XY; Chen Y; Guo SY; Gan Y; Gao ZW; Chen XY; Ding J; He JX; Zhang A; Miao ZH
    Cancer Lett; 2017 Feb; 386():47-56. PubMed ID: 27847302
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial.
    Tutt A; Robson M; Garber JE; Domchek SM; Audeh MW; Weitzel JN; Friedlander M; Arun B; Loman N; Schmutzler RK; Wardley A; Mitchell G; Earl H; Wickens M; Carmichael J
    Lancet; 2010 Jul; 376(9737):235-44. PubMed ID: 20609467
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Hereditary breast and ovarian cancers].
    Gevensleben H; Serçe N; Büttner R
    Pathologe; 2010 Oct; 31(6):438-44. PubMed ID: 20848107
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [PARP inhibitors--theoretical basis and clinical application].
    Dębska S; Kubicka J; Czyżykowski R; Habib M; Potemski P
    Postepy Hig Med Dosw (Online); 2012 May; 66():311-21. PubMed ID: 22706117
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PARP inhibitors stumble in breast cancer.
    Guha M
    Nat Biotechnol; 2011 May; 29(5):373-4. PubMed ID: 21552220
    [No Abstract]   [Full Text] [Related]  

  • 16. Therapeutic potential of poly(ADP-ribose) polymerase inhibitor AG014699 in human cancers with mutated or methylated BRCA1 or BRCA2.
    Drew Y; Mulligan EA; Vong WT; Thomas HD; Kahn S; Kyle S; Mukhopadhyay A; Los G; Hostomsky Z; Plummer ER; Edmondson RJ; Curtin NJ
    J Natl Cancer Inst; 2011 Feb; 103(4):334-46. PubMed ID: 21183737
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Poly(ADP-ribose) polymerase inhibition: a new direction for BRCA and triple-negative breast cancer?
    Plummer R
    Breast Cancer Res; 2011 Aug; 13(4):218. PubMed ID: 21884642
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PARP inhibitors in the management of breast cancer: current data and future prospects.
    Livraghi L; Garber JE
    BMC Med; 2015 Aug; 13():188. PubMed ID: 26268938
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PARP inhibitors and their evolving role in breast cancer.
    Roop RP; Ma CX; Ellis MJ
    Oncology (Williston Park); 2011 Oct; 25(11):1033-4. PubMed ID: 22106554
    [No Abstract]   [Full Text] [Related]  

  • 20. The potential of PARP inhibitors in genetic breast and ovarian cancers.
    Drew Y; Calvert H
    Ann N Y Acad Sci; 2008 Sep; 1138():136-45. PubMed ID: 18837894
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.